

BEST AVAILABLE COPY

07-27-05 17:23 From CLARK & ELBING LLP

+6174287023

T-866 P.002/004 F-085


RECEIVED
CENTRAL FAX CENTER
JUL 27 2005

PATENT
ATTORNEY DOCKET NO. 07891/003006

Certificate of Mailing Date of Deposit: July 27, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted to Examiner Sumesh Kaushal at 571-273-6300 on the date indicated above.

Claire C. Volts
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert G. Korneluk et al. Art Unit: 1636
Serial No.: 10/600,272 Examiner: Kaushal, Sumesh
Filed: June 20, 2003 Customer No.: 21559
Title: MAMMALIAN IAP GENE FAMILY, PRIMERS, PROBES AND
DETECTION METHODS

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), Aegera Therapeutics Inc., the assignee of the entire right, title, and interest in the above-captioned application, seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(2), Aegera Therapeutics Inc. hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the application subsequent to the expiration date of U.S. Patent No. 6,656,704. Aegera Therapeutics Inc. does not disclaim any terminal part of any patent granted on the

rejection.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: July 20 2005

By: Philip Swain

Printed Name: PHILIP SWAIN

Title: DIRECTOR, INTELLECTUAL PROPERTY
For: Aegera Therapeutic Inc.